ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
1. 4ÔÂ22ÈÕ£¬»ª¶«Ò½Ò©È«×Ê×Ó¹«Ë¾ÖÐÃÀ»ª¶«Ðû²¼ÆäHDM1005×¢ÉäÒº»ñÃÀ¹úFDAÅú×¼¿ªÕ¹1ÆÚÁÙ´²ÊÔÑ飬˳Ӧ֢Ϊ³ÉÈ˳¬ÖØ»ò·ÊÅÖÈËȺµÄÌåÖØÖÎÀí¡£HDM1005×¢ÉäÒºÒ»¿î¶àëÄÀàÈËÒȸßѪÌÇËØÑùëÄ-1£¨GLP-1£©ÊÜÌåºÍÆÏÌÑÌÇÒÀÀµÐÔ´ÙÒȵºËضàëÄ£¨GIP£©ÊÜÌåµÄË«°Ðµã³¤Ð§¼¤¶¯¼Á¡£
2. 4ÔÂ23ÈÕ£¬°°Ê¯ÉúÎïÆìÏÂÈ«×Ê×Ó¹«Ë¾ÆÖÈó°ÂÉúÎïÉ걨µÄ²®ÈðÌæÄ᳦ÈܽºÄÒÐÂ˳Ӧ֢ÉÏÊÐÉêÇë»ñµÃÅú×¼£¬Ë³Ó¦Ö¢Îª£ºÓÃÓÚÖÎÁƾ·ÅÁƺÍÌæÄªßò°·£¨TMZ£©ÖÎÁƺ󸴷¢»ò²»¿ÉÄÍÊܵ쬾ßÓÐPTPRZ1-MET£¨ZM£©ÈںϻùÒòµÄÒìÄûÃÊËáÍÑÇâø£¨IDH£©Í»±äÐÍWHO 4¼¶ÐÇÐÎϸ°ûÁö»ò¼ÈÍùÓнϳõ¼¶±ð²¡Ê·µÄ½ºÖÊĸϸ°ûÁö£¨GBM£©³ÉÈË»¼Õß¡£
3. 4ÔÂ23ÈÕ£¬»ÔÈð(Pfizer/PFE.US)Ðû²¼£¬Å·ÃËίԱ»á(EC)Åú×¼ÆäÓë°¬²®Î¬(AbbVie/ABBV.US)ÁªºÏ¿ª·¢µÄEmblaveo(aztreonam-avibactam)ÉÏÊУ¬ÓÃÓÚÖÎÁƳÉÈËÖØ´óÐÔ¸¹Ç»ÄÚѬȾ(cIAI)¡¢Ò½Ôº»ñµÃÐÔ·ÎÑ×(HAP£¬°üÀ¨ºôÎü»úÏà¹ØÐÔ·ÎÑ×[VAP])£¬ÒÔ¼°ÖØ´óÐÔÄò·ѬȾ(cUTI£¬°üÀ¨ÉöÓÛÉöÑ×)¡£¸ÃÒ©ÎﻹÊÊÓÃÓÚÖÎÁÆÓÉÐèÑõ¸ïÀ¼ÊÏÒõÐÔ¾úÒýÆðѬȾµÄ³ÉÈË»¼Õß
4. 4ÔÂ22ÈÕ£¬¿µÏ£ÅµÉúÎï(06185)Ðû²¼Í¨¸æ£¬¹«Ë¾Ñз¢µÄ¶³¸ÉbÐÍÁ÷¸ÐÊÈѪ¸Ë¾ú(Hib)Á¬ÏµÒßÃç(HibÒßÃç)ÒÑ»ñµÃÖлªÈËÃñ¹²ºÍ¹ú¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÅú×¼£¬¿ÉÒÔ¿ªÕ¹Ïà¹ØÁÙ´²ÊÔÑé¡£
1. 4ÔÂ23ÈÕ£¬²ªÁÖ¸ñÒó¸ñº²£¨Boehringer Ingelheim£©ºÍÒæÆÕÉú£¨Ipsen£©¹«Ë¾¾ù¸æ¿¢Êý¶îÁè¼Ý10ÒÚÃÀÔªµÄÑз¢ºÍÔÊÐíÏàÖúÐÒ飬»®·Ö½á¹¹°üÀ¨´úл¹¦Ð§Ïà¹ØÖ¬·¾ÐÔ¸ÎÑ×£¨MASH£©ÔÚÄÚµÄÂýÐԸβ¡ÁìÓòºÍ°ÐÏòRNAµÄС·Ö×ÓÁÆ·¨¡£
1. ¿ËÈÕ£¬À´×Ô¼ÓÀû¸£ÄáÑÇ´óѧÂåÉ¼í¶·ÖУµÄÍŶÓÍ»ÆÆÁËÎÒÃǶԷDZàÂëÇøµÄÈÏÖª£¬ËûÃÇ·¢Ã÷¸ÃÇøÓòµÄDNA²»±àÂ빦ЧÂѰף¬È´·Ç³£Æð¾¢µØ¼ÓÈë×ÅÂѰ׵ÄmRNAˮƽµ÷¿Ø£¬ÕâÒ²¾öÒé×ÅÒÖ°©»ò´Ù°©ÂѰ׵Ä×îÖÕ±í´ïˮƽÆéá«¡£¶ø·Ç±àÂëÇøµÄһЩͻ±ä»áµ¼Ö±¬·¢Òì³£ÊýÄ¿µÄmRNA£¬²¢ÇÒÓë°©Ö¢±¬·¢Î£º¦Óйأ¬Ïà¹ØÑо¿ÒѾ½ÒÏþÔÚ¡¶×ÔÈ»-ͨѶ¡·ÉÏ¡£¡£
[1]Fu, T., Amoah, K., Chan, T.W. et al. Massively parallel screen uncovers many rare 3¡ä UTR variants regulating mRNA abundance of cancer driver genes. Nat Commun 15, 3335 (2024). https://doi.org/10.1038/s41467-024-46795-7